Scholarlink

<p>In vivo characterization of protein structures and structural changes after perturbation is still a major challenge and has impacted our understanding of the molecular events involved in protein misfolding diseases. To identify the true conformational space occupied by proteins in their native state in vivo, we recently developed a structural proteomics method named Covalent Protein Painting (CPP). Here, we show how CPP can be used to identify and quantify the conformational defects of proteins in the misfolding disease Cystic Fibrosis. We first report the discovery of a previously unreported opening mechanism for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) as well as its conformational changes during biogenesis. Then we further reveal how misfolding of different CFTR variants in Cystic Fibrosis disturbs these conformational changes even upon treatment with current approved drugs and suggest possibilities to stabilize misfolded CFTR variants not or less responsive to these drugs such as N1303K CFTR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

In vivo conformational space and defects of misfolded CFTR variants by covalent protein painting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月19日

查看全文
  • Sandra Pankow,
  • Tom Casimir Bamberger,
  • Salvador Martínez-Bartolomé,
  • Robin Park,
  • John R. Yates III

摘要

In vivo characterization of protein structures and structural changes after perturbation is still a major challenge and has impacted our understanding of the molecular events involved in protein misfolding diseases. To identify the true conformational space occupied by proteins in their native state in vivo, we recently developed a structural proteomics method named Covalent Protein Painting (CPP). Here, we show how CPP can be used to identify and quantify the conformational defects of proteins in the misfolding disease Cystic Fibrosis. We first report the discovery of a previously unreported opening mechanism for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) as well as its conformational changes during biogenesis. Then we further reveal how misfolding of different CFTR variants in Cystic Fibrosis disturbs these conformational changes even upon treatment with current approved drugs and suggest possibilities to stabilize misfolded CFTR variants not or less responsive to these drugs such as N1303K CFTR.